On December 1, all the major consumer sectors of A shares rose sharply, and welcomed a good start. At the same time, the investment portfolio and strategic views of major brokers in 212 were also released one after another. According to statistics, 11 brokerage firms including CITIC Securities , Shenwan Hongyuan have announced the list of gold stock in December.
in December gold stocks were released, 15 gold stocks were recommended at the same time, China Life has the highest "gold content"
According to statistics, as of November 30, 11 brokerage firms have recommended a total of 127 gold stocks, covering 30 first-level industries, among which automobiles and biomedicine have harvested 11 gold stocks respectively, and food and beverages have also harvested 10 gold stocks.
Currently, there are 15 companies jointly recommended by more than 2 institutions, among which China Life Insurance is the most recommended, and it is also popular among 4 securities companies, namely Western Securities, Changjiang Securities , Guolian Securities and Guangdong Securities. In addition, Jinde Group is also unanimously favored by three securities companies, while Kweichow Moutai and CATL were previously unanimously favored by them, and no institutions have recommended it yet.
China Life Insurance rose 34.93% in November
Guangdong Securities: The third arrow of real estate landed, the China Securities Regulatory Commission issued capital market five optimization measures to support the healthy development of real estate, loosening of real estate financing eases real estate risks, coupled with the catalysis of long-term interest rates stabilized under the bottom economic recovery, the asset-side catalysis brought about by the stabilization of long-term interest rates is expected to continue, the liability side shows signs of bottom recovery, low valuation and improvement of both asset-liability ends. The company achieved a net profit attributable to shareholders of RMB 31.117 billion in the first three quarters, and the company's liability side was dominant and the asset side was more flexible.
Western Securities: At present, the life insurance industry is in a stage of reform transformation from extensive growth to high-quality growth, and in recent years, insurance companies' liability performance has been under pressure. We expect that the implementation of the new insurance sales regulations may accelerate the transformation of the agent team, the construction of the third pillar of pension account system may accelerate the adjustment of the product structure, and the transformation of the personal insurance industry is expected to bottom out.
Changjiang Securities: Double-click on investment and negative is expected, and it is optimistic about upward elasticity. In the short term, the marginal improvement of the debt side continues to improve, and investment sensitivity has been enhanced. We are optimistic about the valuation repair brought about by the double-click on capital and negative; in the medium and long term, the company leads the industry's development trend and is expected to be the first to complete the reform and transformation of the supply side of team channels, products and services.
Guolian Securities: Recommended reasons 1) The epidemic prevention and control policy continues to optimize and raise the expectations of economic recovery, and the company has pro-cyclical attributes; 2) The real estate support policy continues to relax, effectively improving the company's asset quality expectations; 3) The subsequent stable growth policy is expected to promote the improvement of my country's social financing, drive the upward trend of interest rates, and benefit the company's asset-side expectations; 4) The company has strong beta attributes, and subsequent stock market stabilization will significantly improve the company's investment returns. 5) Liability side: The company started well and performed well, and is expected to resume positive growth, which is better than the industry.
Jindi Group's increase in November 48.85%
Cinda Securities: The old leader operated steadily. In the overall market weakness in 2022H1, the sales scale of the full-caliber 100.6 billion yuan was 100.6 billion yuan, the industry ranking increased against the trend, returning to the top ten echelons; the land resources were of high quality and richness. As of 2022H1, the total land reserves were 61.93 million cubic meters, and the equity land reserves were 28.4 million cubic meters. The total land reserves in first- and second-tier cities accounted for 70%, and the inventory ratio of goods and land was about 4.5, and it is expected to ensure at least 3-4 years of sales cycle.
BOC International : Leading sales growth rate, adhering to the strategy of deepening high-level cities, and stabilizing the basic security pad . The development of diversified businesses has achieved remarkable results and has entered the first echelon of all fields. Construction agency business has grown steadily and rapidly, cultivating the second growth curve.
Zheshang Securities : The company has strong sales resilience and has received support from multiple banks in financing. It is an industry leader with strong comprehensive strength. How to move in
11? A-shares are currently in the bottom area of high cost performance, which is a good layout window
Overall, securities companies are quite optimistic about the stock market in December, believing that the current market is still in the bottom area of high cost performance, which is a good layout window.
Changjiang Securities believes that in the short term, the consolidates , but the risk preference bottom has appeared at the end of October, so there is no need to be pessimistic. The expectation of stable growth at the end of the year has strengthened, and the style is slightly more valuable.In terms of industry allocation, we will pay attention to real estate, home appliances, and information technology in the short term; for next year's layout, we can pay attention to core assets in traditional economic related fields on the left, and continue to focus on information technology in, medicine, and military industry.
Shanxi Securities believes that looking forward to December, the overall market sentiment will improve slightly, and the willingness to allocate foreign capital rebounded, but there are recurring. In addition, the incremental funds of are limited, resulting in the acceleration of rotation of , and the main line is unclear. Shanxi Securities still maintains the current judgment as the window period for layout. Although it remains to be verified when the economy will bottom out and rebound in the end, A-share market is coming out of the bottom. In terms of style, under the current liquidity environment and economic transformation trend, we are still relatively optimistic about the small-cap stock . In terms of the industry, we are optimistic about the real estate chain, banks, and pharmaceuticals with the rebound in the bottom reversal ; machinery with better profit prospects; coal boosted by seasonality, and medium- and long-term allocation is optimistic about military industry and electric new electricity.
11 gold stock performance, 17 gold stocks rose by more than 30%, Zhongsheng Pharmaceutical was elected as the "gold stock king" in November
Review the performance of securities companies' gold stocks in November, as of the close of November 30, among the 343 gold stocks recommended by securities companies in November, a total of 192 individual stocks recorded a certain increase in the month, accounting for about 56%. Among them, 17 individual stocks rose by more than 30% in the month, mainly concentrated in real estate, materials, finance, medical care, industry and other industries.
The highest increase was Zhongsheng Pharmaceutical, recommended by Huaxin Securities, which has accumulated a cumulative increase of up to 78% since November, becoming the king of gold stocks in November. Huaxin Securities believes that the company's research and release of oral small molecule new coronavirus drugs is of strategic significance. At the same time, the company's choice of 3CL protease inhibitors has more potential. In addition, the approval of green channel is accelerated, which is expected to accelerate clinical progress.
This article comes from the financial world
